Reivindicaciones
1. An antagonist of P2X7 receptor for use in the treatment of status epilepticus. 2. An antagonist of P2X7 receptor for use according to claim 1, wherein the antagonist is a selective antagonist. 3. An antagonist of P2X7 receptor, for use according to claim 1, wherein the antagonist is a disubstituted tetrazole of the Formula I, <img class="EMIRef" id="147013315-ib0012" /> wherein, R1 is selected of the groups consisting of cycloalkenyl, cycloalkyl, Heterocyclo, aryl, Heteroaryl, arylalkyl and Heteroarylalkyl; wherein each R1 is substituted with 0, 1, 2, 3, 4 or 5 sustituents which are independently selected from the group consisting of alkyl, alkenyl, alkinyl, nitro, cyano, Halo, -OR<C>, -O(CO)R<c>, -OC(O)OR<c>, -OS(O)<2>R<c>, - SR<C>, -S(O)R<c> -S(O)<2>R<C>, -S(O)<2>OR<c>, -S(O)<2>NR<c>R<d> , -NR<c>R<d>, -N(R<d>)C(O)OR<c>, - N(R<d>)C(O)NR<c>R<d>, -N (R<d>)S(O)<2>NR<c>P<d>, -C(O)R<c>, -C(O)OR<c>, -C(O)NR<c>R<d>, haloalkyl, cianoalkyl, nitroalkyl, -alkylOR<c>, -O(CO)R<c>, -alkylOC(O)OR<c>, -alkylOS(O)<2>R<c>, alkylSR<c>-, -alkylS(O)R<c>, -alkylS(O)<2>R<C>, -alkylS(O)<2>OR<c>, -alkylS(O)<2>NR<c>R<d>, alkylNR<c>R<d>, -alkylN(R<d>)C(O)OR<C>, -alkylN(R<d>)C(O)NR<c>R<d>, -alkylN(R<d>)S(O)<2>NR<c>R<d>, alkylC(O)R<c>, -alkylC(O)OR<C>, -alkylC(O)NR<c>R<d> and R3; provided that, when R1 is arylalkyl or Heteroarylalkyl, D is a bond; R2 is selected of the groups consisting of cycloalkyl, cycloalkenyl, Heterocyclo, aryl and Heteroaryl; wherein each R2 is substituted with 0, 1, 2, 3, 4 or 5 sustituents which are independently selected from the group consisting of alkyl, alkenyl, alkinyl, nitro, cyano, Halo, -OR<C>, -O (CO)R<c>, -OC(O)OR<c>, -OS(O)<2>R<C>, -SR<C>, -S(O)R<c>, - S(O)<2>R<C>, -S(O)<2>OR<c>, -S(O)<2>NR<c>R<d> , -NR<c>R<d>, -N(R<d>)C(O)OR<c>, -N(R<d>)C(O)NR<c>R<d>, - N(R<d>)S(O)<2>NR<c>R<d>, -C(O)R<c>, -C(O)OR<c>, -C(O)NR<c>R<d>, Haloalkyl, cyanoalkyl, nitroalkyl, -alkylR<c>, -O(CO)R<c>, -alkylC(O)OR<C>, -alkylS(O)<2>R<C>, alkylSR<c>, -alkylS(O)R<c>,-alkylS(O)<2>R<C>,-alkylS(O)<2>OR<c>,-alkylS(O)<2>NR<c>R<d>, alkylNR<c>R<d>, -alkylN(R<d>)C(O)OR<C>, - alkyllN(R<d>)C(O)NR<c>R<d>, -alkylN(R<d>)S(O)<2>NR<c>R<d>, alkylC(O)R<c>, -alkylC(O)OR<C>, - alkylC(O)NR<c>R<d> and R3; R3 si selected of the group consisting of cycloalkyl, cycloalkenyl, Heterocyclo, aryl and Heteroaryl; wherein each R3 is substituted with 0, 1, 2, 3, 4 or 5 substituents which are independently selected from the group consisting of alkyl, alkenyl, alkinyl, nitro, cyano, Halo, formyl, Hydroxy, alkoxy, Haloalkoxy, -OC(O)alkyl, -S(O)<2>alkyl, - S(O)<2>NH<2>, -S(O)<2>N(H)(alkyl), -S(O)<2>N(alkyl)<2>, -NH<2>, -N(H)(alkyl), -N(alkyl)<2>, - C(O)(alkyl), -C(O)(OH), -C(O)(Oalkyl), -C(O)NH<2>, -C(O)N(H)(alkyl), -C(O)N(alkyl)<2>, Haloalkyl, formylalkyl, cyanoalkyl, nitroalkyl, Hydroxyalkyl, alkoxyalkyl, Haloalkoxyalkyl, -alkylC(O)alkyl, -alkyl-S(O)<2>alkyl, -alkyl-S(O)<2>NH<2>, -alkylS(O)<2>N(H)(alkyl), -alkyl-S(O)<2>N(alkyl)<2>, -alkyl-NH<2>, -alkyl-N(H)(alkyl), -alkyl-N(alkyl)<2>, -alkyl-C(O)(alkyl),- alkyl-C(O)(OH), -alkyl-C(O)(Oalkyl), -alkyl-C(O)NH<2>, - alkyl-C(O)N(H)(alkyl), and -alkyl-C(O)N(alkyl)<2>; and R<c> y R<d>, in each occurrence, are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl; wherein the aryl, heteroaryl, aryl of the arylalkyl moiety and heteroaryl of the heteroarylalkyl moieties are independently substituted with 0, 1, 2 or 3 substituents which are independently selected from the group consisting of alkyl, halo, haloalkyl, hydroxy, hydroxyalkyl and alkoxialkyl. 4. An antagonist of P2X7 receptor, for use according to claim 3, wherein the antagonist is a disubstituted tetrazole selected from one of the following groups: a) the disubstituted tetrazoles of Formula II <img class="EMIRef" id="147013315-ib0013" /> b) the substituted tetrazoles of Formula III <img class="EMIRef" id="147013315-ib0014" /> wherein R is selected from the group of C<6>H<5>, 2-CH<3>-C<6>H<6>, 2-pyridyl, 3-pyridiyl, 4-pyridyl, 2-CH<3>-3-pyridyl, 3-pyridinylmethyl, 2,4-(CH<3>)<2>-5-thiazolyl, 3,5-(CH<3>)<2>-4-isoxazolyl; c2,3-(CH<3>)<2>-C<6>H<3>, <img class="EMIRef" id="147013315-ib0015" /> wherein, R<2> and R<1> are selected so that when R<2> is 3-pyridyl, R<1> is selected from the group of C<6>H<5>, 2-Cl-C<6>H<4>, 3-Cl-C<6>H<4>, 2,5-Cl<2>-C<6>H<3>, 3,4-Cl<2>-C<6>H<3>, 2-CF<3>-3-F-C<6>H<3>, 2-Cl-3-CF<3>-C<6>H<3>, 2-F-3-CF<3>-C<6>H<3>, 2,3-Cl<2>-4-F-C<6>H<2>, 2,3,4-Cl<3>- C<6>H<2>, when R<2> is C<6>H<5>, R<1> is selected from the group of 4-pyridyl, 5-quinolyl, 8-quinolyl, 2,3-Cl<2>-4-pyrrolidinyl-C<6>H<2>, when R<2> is 2-CH<3>-C<6>H, R<1> is 2,3-(CH<3>)<2>-C<6>H<3>, when R<2> 2-Cl-C<6>H<4>, R<1> is 2,3-(OCH<3>)<2>-C<6>H<3>; d) the substituted tetrazoles of Formula V, <img class="EMIRef" id="147013315-ib0016" /> wherein R<1> is selected from the group of 2,3-Cl<2>-C<6>H<3>, 2,3-Cl<2>-4-F-C<6>H<2>, 2-Cl-3-CF<3>-C<6>H<3>, 2-Cl-3-CF<3>-4-F-C<6>H<2>; e) 1-(2,3-dichlorophenyl)-N-[2-(pyridin-2-yloxy)benzyl]-1H-tetrazol-5-amine (A-839977); or any pharmaceutically acceptable salt thereof. 5. An antagonist of P2X7 receptor for use according to claim 1 or 2, wherein the antagonist is capable to cross the blood brain barrier. 6. An antagonist of P2X7 receptor for use according to claim 5, wherein the antagonist is selected of the group of Brilliant Blue G (BBG), KN-62, A-438079 (3-[[5-(2,3-dichlorophenyl)-1H-tetrazole-1-yl]methyl]pyridine), or any pharmaceutically acceptable salt of decavanadate ((V<10>O<28>)<6->). 7. An antagonist of P2X7 receptor for use according to any one of claims 1 to 6, wherein the subject suffering from status epilepticus is an adult, a child, an infant or a neonate. 8. An antagonist of P2X7 receptor for use according to any one of claims 1 to 7, wherein the antagonist of the P2X7 receptor is administered in adjunction with an anti-convulsant or any other anti-epileptic drug. 9. An antagonist of P2X7 receptor for use according to claim 8, wherein the antagonist of the P2X7 receptor is administered in adjunction with a benzodiapezine. 10. An antagonist of P2X7 receptor for use according to claim 9, wherein the antagonist of the P2X7 receptor is administered in adjunction with lorazepam. 11. An antagonist of P2X7 receptor for use according to any one of claims 8 to 10, wherein the antagonist is administered prior to, contemporaneous with or subsequent to the administration of the anti-convulsant. 12. An antagonist of the P2X7 receptor for use according to any of the preceding claims, wherein the status epilepticus is refractory status epilepticus. 13. An antagonist of the P2X7 receptor for use according to claim 12, wherein the antagonist is A-438079, which is administered in adjunctive treatment with lorazepam. 14. A method of use of an antagonist for treating or preventing the seizure in the status epilepticus in an animal, which method comprises administering to said animal an effective amount of the antagonist of P2X7 receptor. 15. The method according to claim 14, wherein the antagonist is administered to the animal prior to, contemporaneous with, or subsequent to start of the seizure. 16. The method according to claim 14 or 15, wherein the antagonist of P2X7R is administered in combination with an anti-epileptic drug.. 17. The method according to claim 16, wherein the antagonist of P2X7R is administered prior to, simultaneously to, or subsequent to the administration of the anti-epileptic drug. 18. The method according to claim 16 or 17, wherein the anti-epileptic drug is a benzodiazepine. 19. The method according to claim 18, wherein the anti-epileptic drug is lorazepam. 20. The method according to any one of the claims 14 to 19, wherein the antagonist of P2X7R is administered intraperitoneally or intravenously 21. The method of claim 20, wherein the antagonist of P2X7 is capable to cross the blood brain barrier. 22. The method according to any of the claims 14 to 21, for treating or preventing a seizure in refractory status epilepticus. 23. The method according to claim 22, wherein the antagonist is administered in combination with a benzodiazepine. 24. The method according to any one of claims 14 to 23, wherein the animal to treat is a human being. 25. The method according to claim 24, wherein the human being is an adult, a children, an infant or a neonate. 26. A method of use of an antagonist of P2X7R for treating or preventing neonatal seizures or seizures in infants or in children up to five years of age, wherein the antagonist of P2X7R is administered alone or in combination with another approved treatment for neonatal seizures such as a barbiturate, a benzodiazepine, any other approved anti-epileptic drug, or in-trial medication such as bumetanide.
